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Abstract Renal organic anion transporter OAT-K1 was stably
transfected in MDCK cells and examined for its transport
characteristics and membrane localization. OAT-K1 mediated
both uptake and efflux of methotrexate in the apical membranes.
Immunoblotting showed that the apparent molecular mass of the
expressed OAT-K1 was 50 kDa, which was comparable to that
found in the rat renal brush-border membranes. The OAT-K1-
mediated methotrexate transport was significantly inhibited in
the presence of several organic anions such as folate and
sulfobromophthalein. These findings suggest that OAT-K1
mediates bidirectional methotrexate transport across the apical
membranes, and may be involved in the renal handling of
methotrexate.
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1. Introduction
A wide variety of drugs and endogenous compounds are
excreted into the urine by the renal tubular secretion systems
[1,2]. Intensive use of the antifolate methotrexate has been
demonstrated to be e¡ective in the treatment of acute lym-
phocytic leukemia at high dosage [3,4], and of arthritis at
relatively low doses [5]. Because urinary excretion represents
the major route of elimination of this substrate from the body
[6], methotrexate reaches high concentrations in the renal tu-
bules, causing the conditions of nephrotoxicity.
We recently cloned a cDNA encoding a kidney-speci¢c or-
ganic anion transporter, OAT-K1, and demonstrated basolat-
eral uptake of methotrexate and folate in LLC-PK1 cells sta-
bly transfected with OAT-K1 [7]. The OAT-K1 was expressed
in the plasma membranes from the transfectant, showing an
apparent molecular mass of about 70 kDa, similar to its pre-
dicted molecular weight [8]. By reverse transcription-coupled
PCR analysis of OAT-K1 mRNA and Western blotting with
anti-OAT-K1 antibody, we found that the OAT-K1 was lo-
calized in the brush-border membranes of the renal proximal
straight tubules with an apparent molecular mass of about 40
kDa [9]. Studies on the membrane localization of the OAT-K1
and characterization of OAT-K1-mediated methotrexate
transport would suggest its physiological role in renal han-
dling of methotrexate. To obtain more information about
OAT-K1, we have stably transfected the OAT-K1 cDNA
into MDCK cells, and examined the transport characteristics
of the transporter. The present results suggest that OAT-K1
mediates bidirectional transport of methotrexate in renal
brush-border membranes.
2. Materials and methods
2.1. Materials
[3P,5P,7-3H]Methotrexate sodium salt (359 GBq/mmol) was pur-
chased from Amersham Int. (Buckinghamshire, UK), and [3P,5P,7,9-
3H]folate (1232 GBq/mmol) was from Moravek Biochemical, Inc.
(Brea, CA, USA). [3H]Taurocholate (128.39 GBq/mmol) and p-[gly-
cyl-14C]aminohippurate (1.5 GBq/mmol) were obtained from Du
Pont-New England Nuclear Research Products (Boston, MA, USA).
Unlabeled methotrexate and indomethacin were purchased from
Wako Pure Chemical Industries (Osaka, Japan). Unlabeled folate,
sulfobromophthalein, taurocholate and p-aminohippurate were ob-
tained from Nacalai Tesque (Kyoto, Japan). All other chemicals
used for the experiment were of the highest purity available.
2.2. Cell culture and transfection
The parental MDCK cells were cultured in complete culture me-
dium consisting of Dulbecco’s modi¢ed Eagle’s medium (Life Tech-
nologies, Rockville, MD, USA) with 10% fetal calf serum (Microbio-
logical Associates, Bethesda, MD, USA) in an atmosphere of 5%
CO2-95% air at 37‡C. The whole OAT-K1 cDNA was subcloned
into the SalI- and NotI-cut mammalian expression vector pBK-
CMV (Stratagene, La Jolla, CA, USA) [10]. MDCK cells were trans-
fected with pBK-CMV/OAT-K1 or pBK-CMV using the calcium
phosphate coprecipitation technique as described [7]. After incubation
in 0.5 mg/ml G418 (Life Technologies) for 8^10 days, single colonies
were picked up with cloning cylinders for subsequent screening. G418-
resistant clonal cells were analyzed by Northern blotting for the ex-
pression of rat OAT-K1 mRNA. For the transport experiments, cells
were seeded with the complete medium on 35 mm diameter culture
dishes or microporous membrane ¢lters (3 Wm pores, 1 cm2 growth
area) inside a Transwell cell culture chamber (Costar, Cambridge,
MA, USA) at a cell density of 2.0U105 cells/dish or 5U105 cells/¢lter,
respectively.
2.3. Uptake study in OAT-K1-expressing MDCK cells
Uptake measurements were performed as described previously [8]
with some modi¢cations. Cellular uptake of radioactive drugs was
measured using monolayer cultures grown in the 35 mm diameter
dishes. The incubation medium for uptake experiments was Dulbec-
co’s phosphate-bu¡ered saline (pH 7.4) [PBS bu¡er (in mM):
137 NaCl, 3 KCl, 8 Na2HPO4, 1.5 KH2PO4, 1 CaCl2 and 0.5 MgCl2],
containing 5 mM D-glucose (uptake bu¡er). For the e¥ux experi-
ments, cell monolayers grown in the 35 mm diameter dishes were
incubated with 0.8 ml of uptake bu¡er containing [3H]methotrexate
(1 and 10 WM) for 30 min. After the incubation, the cells were washed
once with 2 ml of uptake bu¡er containing 1% bovine serum albumin
(BSA) (pH 7.4) followed by three more washes with 2 ml of BSA-free
uptake bu¡er (pH 7.4) at 4‡C and then incubated with 0.8 ml of
uptake bu¡er containing 1% BSA (pH 7.4) at 37‡C for the speci¢ed
time. At the end of incubation, cells were washed three times in BSA-
free uptake bu¡er at 4‡C. The cells were lysed in 0.5 N NaOH sol-
ution, and then the radioactivity in aliquots was determined in 5 ml of
ACSII (Amersham). The protein content of the solubilized cells was
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determined by the method of Bradford [11], using Bio-Rad Protein
Assay kit (Bio-Rad) with bovine Q-globulin as a standard.
2.4. Northern blot analysis
Total RNA was extracted from rat kidney and MDCK transfec-
tants using the RNeasy spin column (Qiagen, Hilden, Germany). For
Northern blot analysis, 10 Wg of total RNA from rat kidney and
MDCK transfectant was resolved by electrophoresis in 1% agarose
gels containing formaldehyde and transferred onto nylon membranes.
After transfer, blots were hybridized at high stringency (50% forma-
mide, 5USSPE, 5UDenhardt’s solution, 0.2% SDS, 10 Wg/ml salmon
sperm DNA at 42‡C) with a whole OAT-K1 cDNA labeled with [K-
32P]dCTP as described [7].
2.5. Western blot analysis
Rabbit anti-OAT-K1 antibodies raised against the synthetic peptide
corresponding to the 15 COOH-terminal amino acids of OAT-K1 [9]
were used for Western blot analysis after a⁄nity puri¢cation [12].
Crude plasma membrane fractions of either the stably transfected
MDCK cells expressing OAT-K1 (MDCK-OAT-K1), mock-trans-
fected cells (MDCK-pBK) or host MDCK cells were prepared. The
samples were separated by 10% SDS-PAGE and transferred to poly-
vinylidene di£uoride membranes (Hybond-PVDF; Amersham) by
semi-dry electroblotting for 30 min. Blots were blocked, washed and
incubated with the puri¢ed antiserum preabsorbed with the synthetic
antigen peptide (0.5 Wg/ml) or the primary puri¢ed antibody (1:50)
overnight at 4‡C. The blots were washed and the bound antibody was
detected on X-ray ¢lm.
2.6. Functional expression in Xenopus oocytes
An open reading frame of the cDNA encoding rat OAT-K1 was
ampli¢ed by PCR with a set of speci¢c primers, blunted with Klenow
fragment and ligated into the blunt-ended dephosphorylation site of
plasmid XLG vector (provided by Dr. P. Agre), which was con-
structed from pBluescript containing the 5P and 3P non-coding regions
of Xenopus L-globin [13,14]. The recombinants were con¢rmed by
enzymatic nucleotide sequencing. Five nanograms of capped comple-
mentary RNA (cRNA) transcribed in vitro was injected into Xenopus
oocytes. Injected oocytes were maintained in modi¢ed Barth’s me-
dium at 18‡C for 2^3 days. In general, functional expression of rat
OAT-K1 was analyzed by measuring uptake of [3H]methotrexate in
groups of oocytes injected with 50 nl of water or cRNA as described
[15]. Oocytes were incubated for 60 min at 25‡C in an uptake solution
(pH 7.4) (in mM: 100 NaCl, 2 KCl, 1 MgCl2, 1 CaCl2, 10 Tris)
containing 500 nM [3H]methotrexate. After the enhanced metho-
trexate uptake was con¢rmed in the OAT-K1 cRNA-injected oocytes,
e¥ux of [3H]methotrexate was measured. The oocytes were loaded
with 50 nl of [3H]methotrexate (0.6 pmol/oocyte), and e¥ux was im-
mediately determined [16]. At the end of incubation, oocytes were
washed three times in 1.5 ml of ice-cold uptake solution (pH 7.4),
solubilized in 10% SDS solution and then the radioactivity was
determined in 5 ml of ACSII (Amersham) by liquid scintillation
counting.
2.7. Statistical analysis
Data were analyzed statistically using one-way analysis of variance
followed by Fisher’s t-test.
Fig. 1. Expression of OAT-K1 mRNA (A) and protein (B) in MDCK-OAT-K1 cells, and accumulation of [3H]methotrexate by MDCK-OAT-
K1 or MDCK-pBK monolayers from the apical (C) or basolateral (D) side. A: Total RNA (10 Wg) from rat kidney, MDCK, MDCK-pBK
and MDCK-OAT-K1 cells was electrophoresed, blotted, and hybridized with the whole OAT-K1 cDNA as a probe at high stringency. B: Plas-
ma membranes (50 Wg) from MDCK, MDCK-pBK and MDCK-OAT-K1 cells were electrophoresed, blotted, and hybridized with the puri¢ed
anti-OAT-K1 antiserum as primary antibody. C and D: Monolayers of MDCK-OAT-K1 (b) or MDCK-pBK (a) were incubated for the speci-
¢ed period at 37‡C with 100 nM [3H]methotrexate added to either the apical (C; pH 7.4) or basolateral (D; pH 7.4) side. Unlabeled incubation
medium was added to the opposite side (pH 7.4). After incubation, the radioactivity of solubilized cells was counted. Each point represents the
mean þ S.E.M. of three monolayers.
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3. Results
As illustrated in Fig. 1A, OAT-K1 mRNA was expressed in
MDCK cells stably transfected with the rat OAT-K1 cDNA,
MDCK-OAT-K1, which was similar in size to that in rat
kidney, but not in the host MDCK and mock-transfected
MDCK-pBK cells. The immunoreactive protein with an ap-
parent molecular mass of 50 kDa was detected with the anti-
OAT-K1 antiserum in the plasma membranes from MDCK-
OAT-K1 cells, but not from MDCK and MDCK-pBK cells
(Fig. 1B). Fig. 1C and D show the intracellular accumulation
of methotrexate in MDCK-OAT-K1 and MDCK-pBK cells
grown on membrane ¢lters. The accumulation from the apical
side was much higher in the MDCK-OAT-K1 than in the
MDCK-pBK monolayers (Fig. 1C). In contrast, the accumu-
lation from the basolateral side in MDCK-OAT-K1 mono-
layers was comparable to that in the MDCK-pBK monolayers
(Fig. 1D). Therefore, the rat OAT-K1 was suggested to be
expressed functionally in the apical membranes of the trans-
fectant with an apparent molecular mass of 50 kDa, corre-
sponding to OAT-K1 expression in rat kidney [9]. Because the
OAT-K1 was localized in the apical membranes of the
MDCK-OAT-K1 monolayers, further transport studies were
done using the cells grown in the 35 mm culture dishes.
Table 1 summarizes the kinetic parameters for methotrexate
accumulation by MDCK-OAT-K1 cells comparing the values
in LLC-PK1 cells stably transfected with OAT-K1 (LLC-
OAT-K1) [7]. The Km value for methotrexate in the
MDCK-OAT-K1 cells was comparable to that in LLC-
OAT-K1 cells, whereas the Vmax value in the MDCK-OAT-
K1 cells was lower than that in LLC-OAT-K1 cells. Next, we
examined the substrate speci¢city of the MDCK-OAT-K1
cells. Under cis inhibition conditions, all drugs had signi¢cant
inhibitory e¡ects on the [3H]methotrexate accumulation by
the transfectant (Fig. 2).
To investigate transport function of the rat OAT-K1 in the
brush-border membranes, we examined the e¥ux of
[3H]methotrexate in MDCK-OAT-K1 cells. Fig. 3 shows the
e¥ux of methotrexate from the MDCK-OAT-K1 cells. After
methotrexate was preloaded in the monolayers, the e¥ux of
methotrexate in the MDCK-OAT-K1 cells was much greater
than that in the MDCK-pBK cells, suggesting that OAT-K1
mediates bidirectional methotrexate transport across the api-
cal membranes. The e¥ux of methotrexate in MDCK-OAT-
K1 cells was not di¡erent from that in MDCK-pBK when
preloaded with methotrexate at a concentration of 10 WM.
This may be due to the OAT-K1-mediated e¥ux of metho-
trexate being saturated at high intracellular concentrations of
the substrate.
Furthermore, OAT-K1-mediated methotrexate transport
was examined in Xenopus oocytes. When expressed in oocytes,
OAT-K1 stimulated the uptake of [3H]methotrexate and
[3H]folate, but not [3H]taurocholate and [14C]p-aminohippu-
rate (Fig. 4A). We reported that OAT-K1 speci¢cally trans-
ports methotrexate and folate, but not taurocholate and p-
aminohippurate in LLC-OAT-K1 monolayers [7]. After the
OAT-K1-mediated methotrexate uptake was con¢rmed in oo-
cytes, we used the same batch of oocytes for e¥ux study.
Following injection of [3H]methotrexate into water- or
OAT-K1 cRNA-injected oocytes, the oocytes were washed
Table 1
Kinetic parameters of methotrexate transport determined by








MDCK-OAT-K1 cells were grown to con£uence in 35 mm culture
dishes. [3H]Methotrexate accumulation was measured at various
concentrations (0.1^30 WM) for 15 min at 37‡C in the absence and
presence of 1 mM unlabeled methotrexate. After incubation, the ra-
dioactivity of solubilized cells was determined. The speci¢c compo-
nent of the uptake was evaluated kinetically using non-linear least-
squares regression analysis as described previously [7]. Transport ex-
periments for each concentration were performed with three mono-
layers.
aValues are from [7].
Fig. 2. E¡ect of various anionic drugs on [3H]methotrexate accumu-
lation by MDCK-OAT-K1 cells. [3H]Methotrexate accumulation by
MDCK-OAT-K1 cells (100 nM; pH 7.4) cultured in 35 mm dishes
was measured for 15 min at 37‡C in the absence (control) and
presence of indicated drugs at a concentration of 100 WM. After
incubation, the radioactivity of solubilized cells was determined.
MTX, unlabeled methotrexate; BSP, sulfobromophthalein; TCA,
taurocholate; PAH, p-aminohippurate. Data are expressed as % of
the control value (318.6 þ 15.23 fmol/mg protein/15 min). Each col-
umn represents the mean þ S.E.M. of three monolayers. **P6 0.001,
signi¢cantly di¡erent from control.
Fig. 3. Time course of methotrexate e¥ux by MDCK-pBK (A) and
MDCK-OAT-K1 (B) cells. After [3H]methotrexate accumulation at
a concentration of 1 WM (a) or 10 WM (b) for 15 min at 37‡C (pH
7.4), cells were washed and incubated in e¥ux bu¡er for the speci-
¢ed period at 37‡C (pH 7.4). The [3H]methotrexate remaining in
MDCK-pBK (A) or MDCK-OAT-K1 (B) cells was measured. Data
are expressed as % of the time 0 value. Each column represents the
mean þ S.E.M. of three monolayers.
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and then incubated in drug-free solution at 25‡C. As shown
in Fig. 4B, water-injected oocytes exhibited no e¥ux of
[3H]methotrexate. In contrast, rapid methotrexate e¥ux out
of the OAT-K1-expressing oocytes was observed.
4. Discussion
In humans, an administered dose of methotrexate is recov-
ered in mostly unchanged form in the urine, with the renal
elimination involving glomerular ¢ltration, active tubular se-
cretion and reabsorption. Previous studies on clearance ex-
periments and isolated renal tubules indicated that methotrex-
ate secretion was a¡ected by other anionic drugs such as p-
aminohippurate [17] and probenecid [18]. A renal basolateral-
type organic anion/dicarboxylate exchanger, OAT1, is sug-
gested to mediate the basolateral uptake of various organic
anions including methotrexate from the circulation into the
proximal tubular epithelial cells [19]. However, the secretion
mechanisms for methotrexate in the brush-border membranes
have not been fully elucidated. We found that OAT-K1 was
expressed predominantly in renal straight tubules and local-
ized in the brush-border membranes [9]. Moreover, we dem-
onstrated that OAT-K1 was involved in the potential inter-
action sites between methotrexate and non-steroidal
antiin£ammatory drugs in the kidney [8]. Therefore, OAT-
K1-mediated transport of methotrexate in the brush-border
membranes implies a signi¢cance for the pharmacological
role of the transporter in the kidney.
The protein with an apparent molecular mass of 50 kDa in
the plasma membrane fractions of MDCK-OAT-K1 cells, but
not of MDCK-pBK and MDCK cells (Fig. 1B), was smaller
than the calculated molecular mass of 74 kDa of the OAT-K1
[7], but comparable to that found in rat renal brush-border
membranes [9]. In this study, we have found that the OAT-
K1-mediated methotrexate transport was enhanced from the
apical side, but not from the basolateral side, in MDCK-
OAT-K1 monolayers (Fig. 1C,D). Moreover, we reported
that proteolytic cleavage of the translation product of the
OAT-K1 mRNA could occur in the renal tubular cells, there-
by the 40 kDa OAT-K1 protein might be localized in the
brush-border membranes [9]. On the other hand, OAT-K1
protein was found to be localized in the basolateral mem-
branes of the transfected LLC-PK1 cells with an apparent
molecular weight of about 70 kDa [7,8], suggesting a lack of
proteolysis of the protein. Therefore, the proteolytic process-
ing and/or excision of OAT-K1 in renal tubular cells would be
retained in the MDCK cells, but not in the LLC-PK1 cells. A
similar event was reported in the localization of oatp1, a rat
liver organic anion transporting polypeptide [20,21]. The
oatp1 protein was detected in rat liver basolateral membranes
and HeLa transfectant plasma membranes with an apparent
molecular mass of about 80 kDa which was comparable to its
calculated molecular mass of about 74 kDa [21,22]. Moreover,
the oatp1 proteins were detected with apparent molecular
masses of about 33 and 35 kDa in rat renal brush-border
membranes under the reducing condition [21]. However, there
is no evidence that the small type of oatp1 proteins can trans-
port anionic compounds in rat kidney. This is the ¢rst report
that the methotrexate transport activity is conserved with a
small type of OAT-K1 molecule, suggesting the small type of
OAT-K1 protein-mediated methotrexate transport in the renal
brush-border membranes. The precise mechanisms of the
membrane localization of the OAT-K1 and the proteolytic
site in the transporter molecule should be further investigated.
The Km value of methotrexate accumulation from the apical
side in the MDCK-OAT-K1 cells was comparable with that
from basolateral side in the LLC-OAT-K1 monolayers. How-
ever, the Vmax value of the transport in the MDCK-OAT-K1
cells was lower than that in the LLC-OAT-K1 monolayers
(Table 1). There would be a di¡erence in the expression level
of the transporter and/or the methotrexate transport velocity
between the basolateral and apical OAT-K1. The inhibitory
potency of the anionic drugs was in the order methotrex-
ates sulfobromophthaleins folates indomethacins p-amino-
hippuratewtaurocholate (Fig. 2). The order of the inhibitory
potency for these drugs was comparable between LLC-OAT-
K1 [7] and MDCK-OAT-K1 cells. Particularly, p-aminohip-
purate and taurocholate had inhibitory e¡ects on the OAT-
K1-mediated methotrexate transport (Fig. 2), but both com-
pounds were not transported via OAT-K1 (Fig. 4). Both com-
pounds may have binding a⁄nity to OAT-K1 by anionic
charge interaction, but are not translocated via OAT-K1
probably due to their unsuitable structural requirements.
These results suggest that both basolateral and apical OAT-
K1-expressing transfectants show a similar sensitivity against
various anionic drugs. Therefore, the expression system of the
OAT-K1 in the MDCK transfectants should be a useful in
vitro model for studying the mechanisms involved in transport
functions and membrane localization.
The OAT-K1-expressing MDCK transfectants and Xenopus
oocytes have shown methotrexate e¥ux activity (Figs. 3B and
4B). Using inducible HeLa transfectants, bidirectional sulfo-
bromophthalein transport via the oatp1 was reported [22]. In
addition, a rat prostaglandin transporter PGT, which shows
35% amino acid identity to OAT-K1, mediated the bidirec-
tional prostanoid transport in oocytes and HeLa transfectants
[23]. The bidirectional transport activity would be one of the
Fig. 4. Accumulation of anionic drugs (A) and e¥ux of
[3H]methotrexate (B) by Xenopus oocytes. A: Accumulation by oo-
cytes was assayed for 2 h at 25‡C in incubation bu¡er containing
500 nM [3H]methotrexate (MTX), 150 nM [3H]folate, 500 nM
[3H]taurocholate (TCA) and 15 WM of [14C]p-aminohippurate
(PAH), 2 days after injection of 50 nl of water (open column) or in
vitro transcribed rat OAT-K1 cRNA (shaded column; 40 ng/oo-
cyte). Accumulation of each drug is expressed as the uptake clear-
ance. B: E¥ux of [3H]methotrexate by water (a)- or rat OAT-K1
cRNA (b)-injected oocytes was assayed for the speci¢ed period at
25‡C in incubation bu¡er immediately after loading 50 nl of
[3H]methotrexate solution (1.2 WM). Each column or point repre-
sents the mean þ S.E.M. of three (A) or four (B) oocytes.
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features of this oatp gene family. Thereby, OAT-K1 may me-
diate the bidirectional transport of methotrexate across the
apical membranes.
Methotrexate accumulates extensively in the kidney in vivo
[17]. Considering membrane potential, cellular accumulated
organic anions, including methotrexate, are likely to be trans-
ported into the lumen across the brush-border membrane, i.e.
tubular secretion. OAT-K1 could facilitate methotrexate e¥ux
when methotrexate was accumulated in the cytoplasm. There-
fore, OAT-K1 may participate in the tubular secretion of
methotrexate, preventing its potential toxicity.
In conclusion, we have extended the study on functional
characteristics of OAT-K1 using the MDCK transfectant
and Xenopus oocyte expression system. The ¢ndings suggest
that intracellular proteolytic cleavage might be necessary for
the apical localization of OAT-K1, and OAT-K1 mediates
bidirectional methotrexate transport. These data imply that
OAT-K1 may be involved in the renal tubular secretion of
organic anions and play a role in detoxication of methotrexate
from tubular epithelial cells into the urine.
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